Difference between revisions of "Team:BGU Israel"
| Line 449: | Line 449: | ||
<h3>About OrignALS</h3> | <h3>About OrignALS</h3> | ||
<p><br>Established in 2006, EchoSense Ltd. develops innovative ultrasound Doppler systems for the diagnosis and monitoring of cardiac and pulmonary diseases. EchoSense delivers a fast,reliable and non-invasive method of diagnosis and our technology has undergone successful clinical trials in the United States, Europe and Israel. The Echosense research and development center is based in Haifa, Israel.</p> | <p><br>Established in 2006, EchoSense Ltd. develops innovative ultrasound Doppler systems for the diagnosis and monitoring of cardiac and pulmonary diseases. EchoSense delivers a fast,reliable and non-invasive method of diagnosis and our technology has undergone successful clinical trials in the United States, Europe and Israel. The Echosense research and development center is based in Haifa, Israel.</p> | ||
| − | <img class="responsive-img" src="originals_white.png" width="50%"> | + | <img class="responsive-img" src="https://static.igem.org/mediawiki/2018/f/f0/T--BGU_Israel--originals_white.png" width="50%"> |
<img class="img-responsive" src=""> | <img class="img-responsive" src=""> | ||
| Line 457: | Line 457: | ||
<h3>Keep in Touch</h3> | <h3>Keep in Touch</h3> | ||
| − | <li class="footer-list-item"><img class="img-responsive social-icons" src="facebook.png" > @iGEMBGU</li> | + | <li class="footer-list-item"><img class="img-responsive social-icons" src="https://static.igem.org/mediawiki/2018/3/3c/T--BGU_Israel--facebook.png" > @iGEMBGU</li> |
| − | <li class="footer-list-item"><img class="img-responsive social-icons" src="instagram.png" >@igem_2018_bgu</li> | + | <li class="footer-list-item"><img class="img-responsive social-icons" src="https://static.igem.org/mediawiki/2018/e/e9/T--BGU_Israel--instagram.png" >@igem_2018_bgu</li> |
| − | <li class="footer-list-item"><img class="img-responsive social-icons" src="twitter. | + | <li class="footer-list-item"><img class="img-responsive social-icons" src="https://static.igem.org/mediawiki/2018/2/26/T--BGU_Israel--twitter.jpg" > @originalsbgu</li> |
| − | <li class="footer-list-item"><img class="img-responsive social-icons" src="email.png" > bgu_israel@gmail.com</li> | + | <li class="footer-list-item"><img class="img-responsive social-icons" src="https://static.igem.org/mediawiki/2018/8/83/T--BGU_Israel--email.png" > bgu_israel@gmail.com</li> |
</ul> | </ul> | ||
</div> | </div> | ||
| Line 469: | Line 469: | ||
Ben Gurion 1, Beer Sheva 8410501, Israel</li> | Ben Gurion 1, Beer Sheva 8410501, Israel</li> | ||
| − | <li class="footer-list-item"><img class="responsive-img" src="bgu_white.png"></li> | + | <li class="footer-list-item"><img class="responsive-img" src="https://static.igem.org/mediawiki/2018/a/a5/T--BGU_Israel--bgu_white.png"></li> |
</ul> | </ul> | ||
</div> | </div> | ||
Revision as of 11:44, 22 August 2018
<!DOCTYPE html>
Abstract
Recent research studies of Amyotrophic Lateral Sclerosis (ALS) suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:
- We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
- We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.